Skip to main content
Erschienen in: Clinical Research in Cardiology 6/2016

19.12.2015 | Original Paper

β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index

verfasst von: Ulrich Fischer-Rasokat, Jörg Honold, Denise Lochmann, Sebastian Wolter, Christoph Liebetrau, Stephan Fichtlscherer, Helge Möllmann, Ioakim Spyridopoulos, Christian W. Hamm

Erschienen in: Clinical Research in Cardiology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

Patients with left ventricular (LV) diastolic dysfunction are characterized by exertional dyspnoea. Heart rate (HR) reduction by β-blockers can improve exercise tolerance by prolonging LV filling, but their negative inotropic and lusitropic properties can be detrimental in this disease. We tested the effects of administering ivabradine, a HR-lowering drug without impact on cardiac kinetics that may favorably affect diastolic function.

Methods

Twenty-four patients with coronary artery disease (CAD) and normal LV ejection fraction on chronic β-blocker therapy were included. NT-proBNP serum levels were determined prior to and after cardiopulmonary exercise. β-Blockers were then replaced by ivabradine and patients were re-tested after 6 weeks. Patients were initially classified as having a low (E/e′ ≤ 8; n = 11) or high (E/e′ > 8; n = 13) LV filling index.

Results

E/e′ significantly decreased during ivabradine therapy in patients with high E/e′ (10.7 ± 2.9 vs. 8.9 ± 1.7; p < 0.01), whereas no difference occurred in patients with low E/e′ (6.4 ± 0.7 vs. 6.5 ± 1.1; p = ns). With ivabradine, patients with high E/e′ had an increased oxygen uptake at the anaerobic threshold (from 10.8 ± 1.4 to 11.8 ± 1.9 ml/min/kg; p < 0.05) and a steeper slope of the initial oxygen pulse curve (from 293 ± 109 to 359 ± 117 µl/beat/kg/W; p < 0.05). Moreover, patients with high E/e′ had lower NT-proBNP serum levels at rest (169 ± 207 vs. 126 ± 146 pg/ml; p < 0.05) and after exercise (190 ± 256 vs. 136 ± 162 pg/ml; p < 0.05) during ivabradine therapy.

Conclusions

In patients with CAD and elevated E/e′, switching therapy from β-blockers to ivabradine may cause a reduction in LV filling pressures and an improved stroke volume response to exercise.
Literatur
1.
Zurück zum Zitat Bangalore S, Steg G, Deedwania P et al (2012) β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308(13):1340–1349CrossRefPubMed Bangalore S, Steg G, Deedwania P et al (2012) β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308(13):1340–1349CrossRefPubMed
2.
Zurück zum Zitat Ozasa N, Morimoto T, Bao B et al (2013) β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 168(2):774–779CrossRefPubMed Ozasa N, Morimoto T, Bao B et al (2013) β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 168(2):774–779CrossRefPubMed
3.
Zurück zum Zitat Bangalore S, Bhatt DL, Steg PG et al (2014) β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA Trial. Circ Cardiovasc Qual Outcomes 7(6):872–881CrossRefPubMed Bangalore S, Bhatt DL, Steg PG et al (2014) β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA Trial. Circ Cardiovasc Qual Outcomes 7(6):872–881CrossRefPubMed
4.
Zurück zum Zitat Williams B, Lacy PS (2009) Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (conduit artery function evaluation) study: CAFE-heart rate. J Am Coll Cardiol 54(8):705–713CrossRefPubMed Williams B, Lacy PS (2009) Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (conduit artery function evaluation) study: CAFE-heart rate. J Am Coll Cardiol 54(8):705–713CrossRefPubMed
5.
Zurück zum Zitat Borer JS, Le Heuzey JY (2008) Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther 15(5):461–473CrossRefPubMed Borer JS, Le Heuzey JY (2008) Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther 15(5):461–473CrossRefPubMed
6.
Zurück zum Zitat Vilaine JP (2006) The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res Offi J Ital Pharmacol Soc 53(5):424–434 Vilaine JP (2006) The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res Offi J Ital Pharmacol Soc 53(5):424–434
7.
Zurück zum Zitat Colin P, Ghaleh B, Monnet X et al (2003) Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 284(2):H676–H682CrossRefPubMed Colin P, Ghaleh B, Monnet X et al (2003) Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 284(2):H676–H682CrossRefPubMed
8.
Zurück zum Zitat Becher PM, Lindner D, Miteva K et al (2012) Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and beta-receptor blockade. Hypertension 59(5):949–957CrossRefPubMed Becher PM, Lindner D, Miteva K et al (2012) Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and beta-receptor blockade. Hypertension 59(5):949–957CrossRefPubMed
9.
Zurück zum Zitat Kosmala W, Holland DJ, Rojek A et al (2013) Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 62(15):1330–1338CrossRefPubMed Kosmala W, Holland DJ, Rojek A et al (2013) Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 62(15):1330–1338CrossRefPubMed
10.
Zurück zum Zitat Wasserman K, Hansen JE, Sue DY et al (2005) Principles of exercise testing and interpretation, 4th edn. Lippincott Williams & Williams, Philadelphia Wasserman K, Hansen JE, Sue DY et al (2005) Principles of exercise testing and interpretation, 4th edn. Lippincott Williams & Williams, Philadelphia
11.
Zurück zum Zitat Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10(2):165–193CrossRefPubMed Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10(2):165–193CrossRefPubMed
12.
Zurück zum Zitat Simantirakis EN, Nakou ES, Kallergis EM et al (2015) Long-term effect of If-channel inhibition on diastolic function and exercise capacity in heart failure patients with preserved ejection fraction. Int J Cardiol 187:9–11CrossRefPubMed Simantirakis EN, Nakou ES, Kallergis EM et al (2015) Long-term effect of If-channel inhibition on diastolic function and exercise capacity in heart failure patients with preserved ejection fraction. Int J Cardiol 187:9–11CrossRefPubMed
13.
Zurück zum Zitat Williams B, Lacy PS, Thom SM et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113(9):1213–1225CrossRefPubMed Williams B, Lacy PS, Thom SM et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113(9):1213–1225CrossRefPubMed
14.
Zurück zum Zitat Missault LH, Duprez DA, Brandt AA et al (1993) Exercise performance and diastolic filling in essential hypertension. Blood Press 2(4):284–288CrossRefPubMed Missault LH, Duprez DA, Brandt AA et al (1993) Exercise performance and diastolic filling in essential hypertension. Blood Press 2(4):284–288CrossRefPubMed
15.
Zurück zum Zitat Kim HK, Kim YJ, Cho YS et al (2003) Determinants of exercise capacity in hypertensive patients: new insights from tissue Doppler echocardiography. Am J Hypertens 16(7):564–569CrossRefPubMed Kim HK, Kim YJ, Cho YS et al (2003) Determinants of exercise capacity in hypertensive patients: new insights from tissue Doppler echocardiography. Am J Hypertens 16(7):564–569CrossRefPubMed
16.
Zurück zum Zitat Gerdts E, Bjornstad H, Toft S et al (2002) Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). J Hypertens 20(6):1223–1229CrossRefPubMed Gerdts E, Bjornstad H, Toft S et al (2002) Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). J Hypertens 20(6):1223–1229CrossRefPubMed
17.
Zurück zum Zitat Lin FY, Zemedkun M, Dunning A et al (2013) Extent and severity of coronary artery disease by coronary CT angiography is associated with elevated left ventricular diastolic pressures and worsening diastolic function. Journal of cardiovascular computed tomography 7(5):289–96 e1 Lin FY, Zemedkun M, Dunning A et al (2013) Extent and severity of coronary artery disease by coronary CT angiography is associated with elevated left ventricular diastolic pressures and worsening diastolic function. Journal of cardiovascular computed tomography 7(5):289–96 e1
18.
Zurück zum Zitat Neuman Y, Kotliroff A, Bental T et al (2008) Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol 127(2):174–178CrossRefPubMed Neuman Y, Kotliroff A, Bental T et al (2008) Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol 127(2):174–178CrossRefPubMed
19.
Zurück zum Zitat Ciurzynski M, Bienias P, Irzyk K et al (2013) Exaggerated increase of exercise-induced pulmonary artery pressure in systemic sclerosis patients predominantly results from left ventricular diastolic dysfunction. Clin Res Cardiol 102(11):813–820CrossRefPubMedPubMedCentral Ciurzynski M, Bienias P, Irzyk K et al (2013) Exaggerated increase of exercise-induced pulmonary artery pressure in systemic sclerosis patients predominantly results from left ventricular diastolic dysfunction. Clin Res Cardiol 102(11):813–820CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Borlaug BA, Nishimura RA, Sorajja P et al (2010) Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Failure 3(5):588–595CrossRefPubMed Borlaug BA, Nishimura RA, Sorajja P et al (2010) Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Failure 3(5):588–595CrossRefPubMed
21.
Zurück zum Zitat Reil JC, Hohl M, Reil GH et al (2013) Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 34(36):2839–2849CrossRefPubMedPubMedCentral Reil JC, Hohl M, Reil GH et al (2013) Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 34(36):2839–2849CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Drouin A, Gendron ME, Thorin E et al (2008) Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 154(4):749–757CrossRefPubMedPubMedCentral Drouin A, Gendron ME, Thorin E et al (2008) Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 154(4):749–757CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Custodis F, Baumhakel M, Schlimmer N et al (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117(18):2377–2387CrossRefPubMed Custodis F, Baumhakel M, Schlimmer N et al (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117(18):2377–2387CrossRefPubMed
24.
Zurück zum Zitat Yue-Chun L, Teng Z, Na-Dan Z et al (2012) Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. PLoS One 7(6):e39394CrossRefPubMedPubMedCentral Yue-Chun L, Teng Z, Na-Dan Z et al (2012) Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. PLoS One 7(6):e39394CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Busseuil D, Shi Y, Mecteau M et al (2010) Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 117(3):234–242CrossRefPubMed Busseuil D, Shi Y, Mecteau M et al (2010) Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 117(3):234–242CrossRefPubMed
26.
Zurück zum Zitat Kohler AC, Sag CM, Maier LS (2014) Reactive oxygen species and excitation-contraction coupling in the context of cardiac pathology. J Mol Cell Cardiol 73:92–102CrossRefPubMed Kohler AC, Sag CM, Maier LS (2014) Reactive oxygen species and excitation-contraction coupling in the context of cardiac pathology. J Mol Cell Cardiol 73:92–102CrossRefPubMed
27.
Zurück zum Zitat Munzel T, Gori T, Keaney JF Jr et al (2015) Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J 36(38):2555–2564CrossRefPubMed Munzel T, Gori T, Keaney JF Jr et al (2015) Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J 36(38):2555–2564CrossRefPubMed
28.
Zurück zum Zitat Heusch G, Skyschally A, Gres P et al (2008) Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 29(18):2265–2275CrossRefPubMed Heusch G, Skyschally A, Gres P et al (2008) Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 29(18):2265–2275CrossRefPubMed
29.
Zurück zum Zitat Kleinbongard P, Gedik N, Witting P et al (2015) Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br J Pharmacol 172(17):4380–4390CrossRefPubMed Kleinbongard P, Gedik N, Witting P et al (2015) Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br J Pharmacol 172(17):4380–4390CrossRefPubMed
30.
Zurück zum Zitat Fischer-Rasokat U, Honold J, Lochmann D et al (2014) Ivabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections. Clin Res Cardiol 103(6):487–494CrossRefPubMed Fischer-Rasokat U, Honold J, Lochmann D et al (2014) Ivabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections. Clin Res Cardiol 103(6):487–494CrossRefPubMed
31.
Zurück zum Zitat Simon L, Ghaleh B, Puybasset L et al (1995) Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 275(2):659–666PubMed Simon L, Ghaleh B, Puybasset L et al (1995) Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 275(2):659–666PubMed
32.
Zurück zum Zitat Heusch G, Baumgart D, Camici P et al (2000) α-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 101(6):689–694CrossRefPubMed Heusch G, Baumgart D, Camici P et al (2000) α-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 101(6):689–694CrossRefPubMed
33.
Zurück zum Zitat Stringer WW, Hansen JE, Wasserman K (1997) Cardiac output estimated noninvasively from oxygen uptake during exercise. J Appl Physiol 82(3):908–912PubMed Stringer WW, Hansen JE, Wasserman K (1997) Cardiac output estimated noninvasively from oxygen uptake during exercise. J Appl Physiol 82(3):908–912PubMed
34.
Zurück zum Zitat Whipp BJ, Higgenbotham MB, Cobb FC (1996) Estimating exercise stroke volume from asymptotic oxygen pulse in humans. J Appl Physiol 81(6):2674–2679PubMed Whipp BJ, Higgenbotham MB, Cobb FC (1996) Estimating exercise stroke volume from asymptotic oxygen pulse in humans. J Appl Physiol 81(6):2674–2679PubMed
35.
Zurück zum Zitat Klainman E, Fink G, Lebzelter J et al (2002) The relationship between left ventricular function assessed by multigated radionuclide test and cardiopulmonary exercise test in patients with ischemic heart disease. Chest 121(3):841–845CrossRefPubMed Klainman E, Fink G, Lebzelter J et al (2002) The relationship between left ventricular function assessed by multigated radionuclide test and cardiopulmonary exercise test in patients with ischemic heart disease. Chest 121(3):841–845CrossRefPubMed
36.
Zurück zum Zitat Sperling MP, Caruso FC, Mendes RG, Dutra DB, Arakelian VM, Bonjorno JC, Catai AM, Arena R, Borghi-Silva A (2014) Relationship between non-invasive haemodynamic responses and cardiopulmonary exercise testing in patients with coronary artery disease. Clin Physiol Funct Imaging. doi:10.1111/cpf.12197 PubMed Sperling MP, Caruso FC, Mendes RG, Dutra DB, Arakelian VM, Bonjorno JC, Catai AM, Arena R, Borghi-Silva A (2014) Relationship between non-invasive haemodynamic responses and cardiopulmonary exercise testing in patients with coronary artery disease. Clin Physiol Funct Imaging. doi:10.​1111/​cpf.​12197 PubMed
37.
Zurück zum Zitat Mottram PM, Haluska BA, Marwick TH (2004) Response of B-type natriuretic peptide to exercise in hypertensive patients with suspected diastolic heart failure: correlation with cardiac function, hemodynamics, and workload. Am Heart J 148(2):365–370CrossRefPubMed Mottram PM, Haluska BA, Marwick TH (2004) Response of B-type natriuretic peptide to exercise in hypertensive patients with suspected diastolic heart failure: correlation with cardiac function, hemodynamics, and workload. Am Heart J 148(2):365–370CrossRefPubMed
38.
Zurück zum Zitat Marie PY, Mertes PM, Hassan-Sebbag N et al (2004) Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Coll Cardiol 43(3):353–359CrossRefPubMed Marie PY, Mertes PM, Hassan-Sebbag N et al (2004) Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Coll Cardiol 43(3):353–359CrossRefPubMed
39.
Zurück zum Zitat Luchner A, Burnett JC Jr, Jougasaki M et al (1998) Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 32(7):1839–1844CrossRefPubMed Luchner A, Burnett JC Jr, Jougasaki M et al (1998) Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 32(7):1839–1844CrossRefPubMed
Metadaten
Titel
β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index
verfasst von
Ulrich Fischer-Rasokat
Jörg Honold
Denise Lochmann
Sebastian Wolter
Christoph Liebetrau
Stephan Fichtlscherer
Helge Möllmann
Ioakim Spyridopoulos
Christian W. Hamm
Publikationsdatum
19.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 6/2016
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-015-0950-0

Weitere Artikel der Ausgabe 6/2016

Clinical Research in Cardiology 6/2016 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.